Back to News
Market Impact: 0.25
Biocon Signs Brazil Pertuzumab Deal With Bahiafarma And Bionovis
Source: Nasdaq
Healthcare & BiotechProduct LaunchesTrade Policy & Supply Chain
Biocon signed a partnership agreement with Brazil's Bahiafarma and Bionovis covering Pertuzumab, a monoclonal antibody for HER2-positive breast cancer. The collaboration is intended to advance production of the therapy in Brazil, potentially expanding Biocon's access to the Brazilian oncology market.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
More News
- Energy markets are adapting to the Iran war as a ‘forever conflict’ while oil producers keep supplies flowing and avoid ‘mutually assured destruction’
- Vertex reports positive IgAN trial data, FDA decision due Nov. 30
- The real test for Moderna’s cancer vaccine isn’t about beating Keytruda. It’s keeping cancer from coming back in the long term.
- US-Iran war, then and now: How the landscape has changed since February
- J&J prostate cancer drug shows promising tumor responses in early trial
- Boeing 777 freighter output halted for two months over supplier row